The Experts below are selected from a list of 18 Experts worldwide ranked by ideXlab platform
Chaitali Lad - One of the best experts on this subject based on the ideXlab platform.
-
formulation development optimization in vitro charaterization of liquisolid compacts of an Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
-
FORMULATION DEVELOPMENT, OPTIMIZATION & IN VITRO CHARATERIZATION OF LIQUISOLID COMPACTS OF AN Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
Devesh Kapoor - One of the best experts on this subject based on the ideXlab platform.
-
formulation development optimization in vitro charaterization of liquisolid compacts of an Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
-
FORMULATION DEVELOPMENT, OPTIMIZATION & IN VITRO CHARATERIZATION OF LIQUISOLID COMPACTS OF AN Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
Ruchi B Vyas - One of the best experts on this subject based on the ideXlab platform.
-
formulation development optimization in vitro charaterization of liquisolid compacts of an Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
-
FORMULATION DEVELOPMENT, OPTIMIZATION & IN VITRO CHARATERIZATION OF LIQUISOLID COMPACTS OF AN Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
Manish Patel - One of the best experts on this subject based on the ideXlab platform.
-
formulation development optimization in vitro charaterization of liquisolid compacts of an Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
-
FORMULATION DEVELOPMENT, OPTIMIZATION & IN VITRO CHARATERIZATION OF LIQUISOLID COMPACTS OF AN Oxicam Derivative
Journal of Drug Delivery and Therapeutics, 2016Co-Authors: Devesh Kapoor, Manish Patel, Ruchi B Vyas, Chaitali LadAbstract:The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble pirOxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of pirOxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of Oxicam Derivative, which in turn promotes in enhancing bioavailability. Keywords: PirOxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
Saraf Shailendra Kumar - One of the best experts on this subject based on the ideXlab platform.
-
development of melOxicam formulations utilizing ternary complexation for solubility enhancement
Pakistan Journal of Pharmaceutical Sciences, 2011Co-Authors: Saraf Shubhini Awasthi, Tripathi Girish Kumar, Pandey Manisha, Yadav Preeti, Saraf Shailendra KumarAbstract:MelOxicam (an Oxicam Derivative), a relatively new cyclo-oxygenase inhibitor, is a member of enolic acid group of non-steroidal anti-inflammatory drugs. It is generally used in the treatment of rheumatoid arthritis, osteoarthritis and other joint pains. MelOxicam is practically insoluble in water (8µg/ml), which directly influences the C(max), T(max), as well as the bioavailability of the drug. In the present study, an attempt has been made to improve the dissolution of MelOxicam by preparation of its solid dispersion using β-cyclodextrin blended with various water soluble polymer carriers i.e., HPMC (methocel IH), methylcellulose (400cps), PVP K30, HPMC (K(4)M), HPMC (50cps). It is reported that when small amount of water soluble polymer is added to β-cyclodextrin, its nature of solubilization significantly increases due to increase in the apparent complex stability constant. Phase solubility studies were carried out to evaluate the solubilizing power of β-cyclodextrin along with various water soluble polymers. The solid dispersion was prepared and formulated into tablets and suspension, which were evaluated on the basis of various official tests. All the studies suggest that formulations of MelOxicam utilizing solid dispersion technique significantly enhances solubility (90 µg/ml) of the drug and results in superior formulations of the drug by using β-cyclodextrin blended with 0.12% w/w HPMC (Methocel IH). Ternary complexation is a valuable tool for solubility enhancement of drugs.
